Systemic Delivery of Bone Marrow–Derived Mesenchymal Stem Cells to the Infarcted Myocardium: Feasibility, Cell Migration, and Body Distribution

By I. Barbash, P. Chouraqui, J. Baron, M. Feinberg, S. Etzion, A. Tessone, L. Miller, E. Guetta, D. Zipori, L. Kedes and 2 more. Circulation, 2003

1,266 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/2bfdc0857e0201d6560c05a6b86e5e82030ba3bc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. G. T. Huang
2. S. Shi
3. S. Gronthos
4. J. Karp
5. Grace Sock Leng Teo
6. Rocky S. Tuan
7. A. Caplan

In Molecular Biology

1. S. Shi
2. G. T. Huang
3. S. Gronthos
4. W. Stetler-Stevenson
5. Toren Finkel
6. Navdeep S. Chandel
7. N. Tonks

In Surgery

1. J. Karp
2. Grace Sock Leng Teo

Citations in the corpus

• Mesenchymal stem cell homing: the devil is in the details. (2009, positive): “IV delivery is the least invasive; however, IC and IA delivery have led to higher engraftment rates than IV delivery in certain models of MI (Barbash et al., 2003; Freyman et al., 2006).”
• Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma (2006, background): “MSCs also appear to have the ability to home to sites of tissue injury (15, 16).”
• Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model (2013, background): “However, the underlying mechanism remains controversial due to the poor viability and considerable death of the engrafted cells in the infracted myocardium as a result of death cues including hypoxia, inflammatory cytokines, and proapoptotic factors, no matter they are systemically [3] or locally ad”
• Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion (2012, methodology): “ORIGINAL RESEARCH ARTICLE published: 26 September 2012 doi: 10.3389/fimmu.2012.00297 Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion”
• Multipotential differentiation of adipose tissue-derived stem cells. (2005, background): “While this therapeutic regimen has had a substantial impact Keio J Med 2005; 54 (3): 132–141 135”
• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, neutral): “STRIOGA ET AL. shown that often, most of the systemically administered MSCs are entrapped within the lungs [83,84].”
• Mesenchymal Stem Cells Derived from Dental Tissues vs. Those from Other Sources: Their Biology and Role in Regenerative Medicine (2009, background): “Some studies have reported the myogenic potential of MSCs, following the delivery of BMMSCs into muscle tissues, especially the myocardium, in animal models (Ferrari et al., 1998; Orlic et al., 2001; Barbash et al., 2003; Gojo et al., 2003).”